Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tulisokibart - Merck & Co

Next Previous
Drug Profile

Tulisokibart - Merck & Co

Alternative Names: MK-7240; PRA-023

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prometheus Biosciences
  • Developer Merck & Co; Prometheus Biosciences
  • Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Crohn's disease; Ulcerative colitis
  • Phase II Hidradenitis suppurativa; Systemic scleroderma
  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 14 Jul 2025 Prometheus Biosciences completes the phase II ARTEMIS-UC trial in Ulcerative colitis in USA, Australia, Belgium, Canada, Czech Republic, France, Georgia, Hungary, Israel, Italy, Poland, United Kingdom (IV) (NCT04996797)
  • 09 Jun 2025 Phase-II clinical trials in Hidradenitis suppurativa (Treatment-resistant) in USA (SC) (NCT06956235)
  • 28 May 2025 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers) in USA (SC, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top